Hydrophobicity engineering to increase solubility and stability of a recombinant protein from respiratory syncytial virus.

Site-directed mutagenesis has been employed to engineer the hydrophobic properties of a 101-amino-acid fragment from the human respiratory syncytial virus (RSV) major glycoprotein (G protein). When this protein was produced in Escherichia coli, more than 70% of the gene product was found as inclusion bodies, and the product recovered from the soluble fraction was severely degraded. Substitution of two cysteine residues for serine residues, did not significantly change the solubility or stability of the gene product. In contrast, a dramatic increase in both solubility and stability was achieved by multiple engineering of hydrophobic phenylalanine residues. As compared to the non-engineered protein, the fraction of soluble protein in vivo could be increased from 27% to 75%. Surprisingly, this effect was accompanied by a remarkable increase in stability. The in vitro solubility of the purified gene products was similarly increased approximately fivefold. Structural studies using circular dichroism suggest that the two engineered fragments have a distribution of secondary-structure elements similar to the non-engineered fragment. In addition, the two engineered G-protein variants were demonstrated to be at least in part antigenically authentic to the non-engineered gene product. These results demonstrate that engineering of hydrophobic residues can be used as a tool to increase the solubility and proteolytic stability of poorly soluble and labile proteins.

[1]  M. Uhlén,et al.  Enhanced in vitro refolding of insulin-like growth factor I using a solubilizing fusion partner. , 1994, Biochemistry.

[2]  B. García-Barreno,et al.  Loss of conserved cysteine residues in the attachment (G) glycoprotein of two human respiratory syncytial virus escape mutants that contain multiple A-G substitutions (hypermutations). , 1994, Virology.

[3]  C. Schein.  Solubility and secretability. , 1993, Current opinion in biotechnology.

[4]  M. Uhlén,et al.  Mutational analysis of the interaction between staphylococcal protein A and human IgG1. , 1993, Protein engineering.

[5]  A. Martín-Gallardo,et al.  Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium. , 1993, The Journal of general virology.

[6]  J. Mccoy,et al.  A Thioredoxin Gene Fusion Expression System That Circumvents Inclusion Body Formation in the E. coli Cytoplasm , 1993, Bio/Technology.

[7]  E. Sutherland,et al.  Analysis of disulphide bridge function in recombinant bovine prolactin using site-specific mutagenesis and renaturation under mild alkaline conditions: a crucial role for the central disulphide bridge in the mitogenic activity of the hormone. , 1992, Protein Engineering.

[8]  P. Collins,et al.  Oligomerization and post-translational processing of glycoprotein G of human respiratory syncytial virus: altered O-glycosylation in the presence of brefeldin A. , 1992, The Journal of general virology.

[9]  J. Bailey,et al.  Cysteine to Serine Substitutions in Basic Fibroblast Growth Factor: Effect on Inclusion Body Formation and Proteolytic Susceptibility During in Vitro Refolding , 1992, Bio/Technology.

[10]  P. Collins,et al.  Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus. , 1991, The Journal of general virology.

[11]  H. Binz,et al.  Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein. , 1991, Virology.

[12]  C. Schein,et al.  Optimizing protein folding to the native state in bacteria. , 1991, Current opinion in biotechnology.

[13]  G. L. Toms.  Vaccination against respiratory syncytial virus: problems and progress. , 1991, FEMS microbiology immunology.

[14]  A. Martín-Gallardo,et al.  Expression of the F glycoprotein gene from human respiratory syncytial virus in Escherichia coli: mapping of a fusion inhibiting epitope. , 1991, Virology.

[15]  A. Kondo,et al.  Engineering Proteins to Enhance their Partition Coefficients in Aqueous Two-Phase Systems , 1991, Bio/Technology.

[16]  S. Enfors,et al.  Factors influencing inclusion body formation in the production of a fused protein in Escherichia coli , 1991, Applied and environmental microbiology.

[17]  Mathias Uhlén,et al.  Facilitated In Vitro Refolding of Human Recombinant Insulin-Like Growth Factor I Using a Solubilizing Fusion Partner , 1991, Bio/Technology.

[18]  R. Lerner,et al.  A subgroup-specific antigenic site in the G protein of respiratory syncytial virus forms a disulfide-bonded loop , 1990, Journal of virology.

[19]  M. Uhlén,et al.  A dual expression system for the generation, analysis and purification of antibodies to a repeated sequence of the Plasmodium falciparum antigen Pf155/RESA. , 1989, Journal of immunological methods.

[20]  Catherine H. Schein,et al.  Production of Soluble Recombinant Proteins in Bacteria , 1989, Nature Biotechnology.

[21]  M. Uhlén,et al.  Different Approaches to Stabilize a Recombinant Fusion Protein , 1989, Bio/Technology.

[22]  B. Moss,et al.  Processing, surface expression, and immunogenicity of carboxy-terminally truncated mutants of G protein of human respiratory syncytial virus , 1989, Journal of virology.

[23]  C. Gross,et al.  Escherichia coli heat shock gene mutants are defective in proteolysis. , 1988, Genes & development.

[24]  M. Uhlén,et al.  Approaches to Solid Phase DNA Sequencing , 1988 .

[25]  M. Uhlén,et al.  Analysis and use of the serum albumin binding domains of streptococcal protein G , 1988, Journal of molecular recognition : JMR.

[26]  W C Johnson,et al.  Variable selection method improves the prediction of protein secondary structure from circular dichroism spectra. , 1987, Analytical biochemistry.

[27]  P. Collins,et al.  The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Uhlén,et al.  A synthetic IgG-binding domain based on staphylococcal protein A. , 1987, Protein engineering.

[29]  F. Marston.  The purification of eukaryotic polypeptides synthesized in Escherichia coli. , 1986, The Biochemical journal.

[30]  B. Moss,et al.  Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Yung,et al.  Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Ptashne,et al.  Gene regulation at the right operator (OR) bacteriophage lambda. I. OR3 and autogenous negative control by repressor. , 1980, Journal of molecular biology.

[33]  M. Uhlén,et al.  Bidirectional solid-phase sequencing of in vitro-amplified plasmid DNA. , 1991, BioTechniques.

[34]  W C Johnson,et al.  Protein secondary structure and circular dichroism: A practical guide , 1990, Proteins.

[35]  B. Nilsson,et al.  Fusions to staphylococcal protein A. , 1990, Methods in enzymology.

[36]  R. Chanock,et al.  Respiratory Syncytial Virus , 1976 .